Drugs / SOMATROPINE
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT01626833 Comparator | Mar 2013 → Mar 2021 | anorexia nervosa, osteoporosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00476385 Background | Jun 2003 → Dec 2005 | pituitary deficiency | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | somatropine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00476385 ↗ |
| Known as | Norditropine simplexx | “SOMATROPINE* : Norditropine® simplexx®” NCT01626833 ↗ |
| Modality | Protein / enzyme biologic | “human growth hormone (GH) injections” PMID 33772303 ↗ Jun 2021 |
| Route | Subcutaneous | “subcutaneous injections” NCT00476385 ↗ |